Hikma Chops $2.7B Boehringer Generics Offer By 20%
U.K. drugmaker Hikma said Wednesday it has slashed nearly 20 percent from its $2.7 billion offer to buy Boehringer's U.S. generics business, after discovering the unit's 2015 revenue would be lower...To view the full article, register now.
Already a subscriber? Click here to view full article